Setting the global standard of diagnostic care
At Mayo Clinic Laboratories, we believe all patients deserve access to world-class diagnostic care. We work with hospitals and healthcare providers around the world to deliver unparalleled expertise and innovative diagnostic evaluations that solve the most complicated cases.
Fully integrated with Mayo Clinic and backed by more than 150 years of clinical experience, Mayo Clinic Laboratories was built upon a tradition of knowledge sharing to improve healthcare around the world. When you work with us, you gain access to the world’s most sophisticated test menu, world-renowned experts, and educational opportunities to strengthen your practice, advance knowledge, and improve patient outcomes.
Focused on quality
At Mayo Clinic Laboratories, test development is based on patient need and guided by quality management protocols modeled on standards and guidelines from the Clinical and Laboratory Standards Institute. Our extensive test validation includes a breadth of specimens with rare abnormalities. Our laboratories are CLIA-certified and CAP-accredited, and we participate in U.S. and international proficiency programs.
Commitment to education
The exchange of knowledge is a founding principle of Mayo Clinic. In this tradition, we provide a wide range of educational offerings to help our clients increase understanding.
- Regionally based clinical specialists guide best practices through physician education.
- Access to Mayo Clinic Laboratories education and insight articles.
- Many courses offer CME credits.
- Online trainings are available, such as “Dangerous Goods Shipping,” with printable certificates.
Enhanced patient outcomes
Mayo Clinic Laboratories is dedicated to the health and well-being of our patients, which means helping providers deliver care in their local settings through the utilization of our comprehensive subspecialty test menu. Our mission is grounded in our belief that the patient’s needs are paramount, and our clients receive access to:
- Expert-developed algorithms that ensure the right patient receives the right test.
- Testing for rare and complex conditions, with some of that testing exclusive to Mayo Clinic Laboratories.
- Expeditious results due to continuous test processing.
“We treat all of the specimens we receive with the same high degree of care and quality, regardless of where the sample is coming from. We could be testing a sample from a patient that lives in Rochester, Minnesota, or from someone that lives halfway across the world.”
Bobbi Pritt, M.D., Director of the Clinical Parasitology Laboratory
OUR DIFFERENCE
News and updates
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss troublesome organisms making headlines.
For patients with chronic lymphocytic leukemia (CLL) — the most common leukemia in adults — advanced testing can not only provide valuable information about their disease state, but peace of mind in the face of a progressive, incurable illness. Oftentimes, however, complex molecular and genetic tests to identify biomarker cues about disease trajectory and treatment intolerance are not performed, putting patients at risk for unmet expectations and unsatisfactory outcomes.
The genetic variability of glioma, and its more advanced relative glioblastoma, has made genetic testing to identify biomarkers associated with prognosis and treatment effectivity an integral component of care plan development. However, the acceleration of brain tumor research and discovery translates into an ever-changing testing environment.
Kevin Halling, M.D., Ph.D., explains how the MayoComplete Solid Tumor panel uses next-generation sequencing to assess 514 clinically significant, cancer-related genes for genetic alterations that offer insight on treatment effectivity.
A collaborative study between Mayo Clinic and the University of Illinois debunked the previous consensus about how kidney stones grow.
Part II of this series shows how a breakthrough discovery about how kidney stones form may open the way for new, unorthodox treatments. The discovery was made possible by joining University of Illinois’ geology and biology forces with Mayo Clinic’s urology and nephrology expertise.
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, hosts this episode of the "Answers From the Lab" podcast. He’s joined by Gianluca Pettiti, senior vice president and president of specialty diagnostics at Thermo Fisher Scientific to discuss their organizations’ collaboration and its value for patients.
When most of the world was still struggling to understand how COVID-19 would affect their lives, Atria Senior Living took steps to protect their vulnerable residents and staff.
In this month’s “Hot Topic,” Andrew McKeon, M.B., B.Ch., M.D., reviews the use of neurological phenotype-based evaluations, the move away from the paraneoplastic evaluation, and upcoming changes to test profiles.
In this episode, Vlad Vasile, M.D., Ph.D., assistant professor of Laboratory Medicine and Pathology and cardiologist at Mayo Clinic, discusses cardiovascular risk testing, including biomarkers and clinical implications.
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., discuss the future of laboratory medicine in a post-pandemic world.
Mayo Clinic Laboratories now offers a noninvasive approach for the molecular detection of H. pylori, with results that include prediction of clarithromycin resistance delivered within 24 hours.
In this episode, Jeffrey (Jeff) Meeusen, Ph.D., assistant professor of Laboratory Medicine and Pathology and clinical chemist in the Division of Clinical Core Laboratory Services at Mayo Clinic, discusses the interface between subspecialties, as well as sustaining bridges between laboratory medicine and cardiology.